<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02937116</url>
  </required_header>
  <id_info>
    <org_study_id>CIBI308A101</org_study_id>
    <nct_id>NCT02937116</nct_id>
  </id_info>
  <brief_title>First in Human Study of IBI308 in Chinese Subjects With Advanced Solid Tumors</brief_title>
  <official_title>An Open-Label, Multicenter Study of IBI308 in Subjects With Selected Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Innovent Biologics (Suzhou) Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Innovent Biologics (Suzhou) Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability and efficacy of IBI308&#xD;
      monotherapy or in combination with chemotherapy in patients with certain types of advanced&#xD;
      solid tumors. Another purpose is to determine the pharmacokinetics, pharmacodynamics and&#xD;
      immunogenicity of IBI308.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study which consists of phase 1a study (dose escalation stage) and phase 1b study&#xD;
      (expansion stage). Phase 1a study will adopt the classical 3+3 dose escalation design,&#xD;
      exploring safety and tolerance of 4 dose cohorts (1mg/kg, 3mg/kg, 200mg and 10mg/kg) and&#xD;
      determining the recommended dose for phase 1b study. Phase 1b is expansion study of 8 cohorts&#xD;
      which will evaluate anti-tumor efficacy and safety of eight IBI308 monotherapy or in&#xD;
      combination with chemotherapy. Cohort A is IBI308 monotherapy for advanced melanoma. Cohort B&#xD;
      is IBI308 monotherapy for advanced digestive system carcinoma or neuroendocrine neoplasm&#xD;
      after failure or intolerance of first line standard therapy. Cohort C is IBI308 monotherapy&#xD;
      for advanced non-small cell lung cancer (NSCLC) after failure or intolerance of first line&#xD;
      standard therapy. Cohort D is IBI308 in combination with cisplatin and pemetrexed for&#xD;
      treatment naïve locally advanced, recurrent or metastatic non-squamous NSCLC. Cohort E is&#xD;
      IBI308 in combination with gemcitabine and cisplatin for treatment-naïve locally advanced,&#xD;
      recurrent or metastatic squamous NSCLC. Cohort F is IBI308 in combination with oxaliplatin&#xD;
      and capecitabine for treatment naïve locally advanced gastric or gastroesophageal junction&#xD;
      adenocarcinoma. Cohort G is IBI308 in combination with etoposide and cisplatin for treatment&#xD;
      naïve locally advanced, recurrent or metastatic high grade(G3) neuroendocrine tumor. Cohort H&#xD;
      is IBI308 in combination with irinotecan and 5-FU for advanced high grade(G3) neuroendocrine&#xD;
      tumor after failure of first line standard therapy. Phase 1a and 1b consist of screening&#xD;
      period (28 days before enrollment), treatment period and follow up period (every 3 months&#xD;
      until death or the end of study). In phase 1a, dose limiting toxicity (DLT) will be recorded&#xD;
      for up to 28 days after the 1st dose of IBI308. Efficacy will be evaluated by RECIST v1.1.&#xD;
      Adverse events will be monitored throughout the study. Further exploration of&#xD;
      pharmacokinetic/pharmacodynamics and immunogenicity information will be assessed throughout&#xD;
      the trial.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 19, 2016</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Actual">October 19, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants Experiencing Dose-limiting Toxicities (DLTs)</measure>
    <time_frame>Up to 28 days in Cycle 1</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of All Study Participants Who Demonstrate a Tumor Response</measure>
    <time_frame>Through out the study (up to 2 years)</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Objective Response Rate (ORR) According to RECIST 1.1 as Assessed by Independent Review Committee by Investigator</measure>
    <time_frame>Through out the study (up to 2 years)</time_frame>
    <description>ORR was defined as the percentage of participants in the analysis population who had achieved BOR of CR or PR according to RECIST 1.1.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PFS According to RECIST 1.1 as Assessed by Investigator</measure>
    <time_frame>Through out the study (up to 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DOR According to RECIST 1.1 as Assessed by Investigator</measure>
    <time_frame>Through out the study (up to 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TTR According to RECIST 1.1 as Assessed by Investigator</measure>
    <time_frame>Through out the study (up to 2 years)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OS for Participants</measure>
    <time_frame>Through out the study</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Concentration-time Curve From Zero Time (Predose) to the Time of the Last Measurable Concentration (AUC0-t)</measure>
    <time_frame>Cycle 1: pre-dose, post-dose at 0, 1, and 6 hours, and Days 2, 3, 8, 15, and 22, and 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration (Cmax) of Sintilimab in Solid Tumor Participants</measure>
    <time_frame>Cycle 1: pre-dose, post-dose at 0, 1, 6 hours, and Days 2, 3, 8, 15, and 22, and 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Concentration (Tmax) of Sintilimab in Solid Tumor Participants</measure>
    <time_frame>Cycle 1: pre-dose, post-dose at 0, 1, 6 hours, and Days 2, 3, 8, 15, and 22, and 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Half-life (t1/2) of IBI308 in Plasma After Single Dose Administration</measure>
    <time_frame>Cycle 1: pre-dose, post-dose at 0, 1, 6 hours, and Days 2, 3, 8, 15, and 22, and 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution of IBI308 in Plasma After Single Dose Administration</measure>
    <time_frame>Cycle 1: pre-dose, post-dose at 0, 1, 6 hours, and Days 2, 3, 8, 15, and 22, and 29</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance of IBI308 in Plasma After Single Dose Administration</measure>
    <time_frame>Cycle 1: pre-dose, post-dose at 0, 1, 6 hours, and Days 2, 3, 8, 15, and 22, and 29</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">233</enrollment>
  <condition>Cancer, Solid Tumor</condition>
  <arm_group>
    <arm_group_label>Phase 1a</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive IBI308 1mg/kg, 3mg/kg or 10mg/kg intravenous every 2 weeks, or 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity.&#xD;
Drug: IBI308</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b Cohort A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive IBI308 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.&#xD;
Drug: IBI308</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b Cohort B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive IBI308 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.&#xD;
Drug: IBI308</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b Cohort C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive IBI308 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.&#xD;
Drug: IBI308</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b Cohort D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive IBI308 200mg in combination with cisplatin 75mg/m2 and pemetrexed 500mg/m2 intravenously every 3 weeks for upto 4 cycles, and those who haven't progressed will receive maintenance treatment of IBI308 200mg in combination with pemetrexed 500mg/m2 intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.&#xD;
Drug: IBI308/Cisplatinum/Pemetrexed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b Cohort E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive IBI308 200mg and cisplatin 75mg/m2 intravenously every 3 weeks in combination with gemcitabine 1250mg/m2 intravenously day 1 and 8 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.&#xD;
Drug: IBI308\gemcitabine\cisplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b Cohort F</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive IBI308 200mg and oxaliplatin 130mg/m2 intravenously every 3 weeks in combination with capecitabine 1000mg/m2 orally day 1 to 14 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.&#xD;
Drug: IBI308\oxaliplatin\capecitabine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b Cohort G</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive IBI308 200mg in combination with cisplatin 75mg/m2 intravenously and etoposide 100mg/m2 intravenously day 1 to 3 of every 3 weeks for upto 6 cycles. Those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.&#xD;
Drug: IBI308\etoposide\cisplatin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Phase 1b Cohort H</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive IBI308 200mg in combination with irinotecan 125mg/m2 intravenously day 1and 8 and 5-FU 1000mg/m2 intravenously day 1 to 3 of every 3 weeks for upto 6 cycles.Those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.&#xD;
Drug: IBI308\irinotecan\5-FU</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI308</intervention_name>
    <arm_group_label>Phase 1a</arm_group_label>
    <arm_group_label>Phase 1b Cohort A</arm_group_label>
    <arm_group_label>Phase 1b Cohort B</arm_group_label>
    <arm_group_label>Phase 1b Cohort C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI308\Cisplatinum\Pemetrexed</intervention_name>
    <arm_group_label>Phase 1b Cohort D</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI308\cisplatin\gemcitabine</intervention_name>
    <arm_group_label>Phase 1b Cohort E</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI308\oxaliplatin\capecitabine</intervention_name>
    <arm_group_label>Phase 1b Cohort F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI308\etoposide\cisplatin</intervention_name>
    <arm_group_label>Phase 1b Cohort G</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IBI308\irinotecan\5-FU</intervention_name>
    <arm_group_label>Phase 1b Cohort H</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status grade 0 or 1&#xD;
&#xD;
          -  Adequate bone marrow, liver, and renal function defined as: 1) Absolute neutrophil&#xD;
             count &gt;= 1.5* 10^9 cells/litre (L); 2) Platelets &gt;=100 x 10^9 cells/L; 3) Hemoglobin&#xD;
             &gt;= 9 gram/deciliter (g/dL); 4) Alanine aminotransferase (ALT) and aspartate&#xD;
             aminotransferase (AST) &lt;= 2.5 * upper limit of normal (ULN) for participants without&#xD;
             hepatic cell cancer and hepatic metastasis, ALT and AST &lt;= 5 * ULN for participants&#xD;
             with hepatic cell cancer or hepatic metastasis; 5) Total bilirubin (TBIL) &lt; 1.5 * ULN&#xD;
             for participants without hepatic cell cancer, hepatic metastasis and&#xD;
             confirmed/suspicious Gilbert syndrome, TBIL &lt; 3 * ULN for participants with hepatic&#xD;
             cell cancer, hepatic metastasis or confirmed/suspicious Gilbert syndrome; 6)&#xD;
             Creatinine determined by serum creatinine levels &lt;=1.5 * ULN or a calculated&#xD;
             creatinine clearance of &gt;= 50 mL/min/1.73 m^2; 7) urine protein -~+, 24 hour urine &lt; 1&#xD;
             gram for participants with urine protein ++ or above; 8) activated partial&#xD;
             thromboplastin time and international normalized ratio &lt;= 1.5 * ULN; 9) thyroid&#xD;
             stimulating hormone and free thyroxine 4 within normal range&#xD;
&#xD;
          -  Tumor type&#xD;
&#xD;
               -  Phase 1a: advanced solid tumors after failure of standard therapy&#xD;
&#xD;
               -  Phase 1b Cohort A: cytologically or histologically confirmed advanced melanoma&#xD;
&#xD;
               -  Phase 1b Cohort B: cytologically or histologically confirmed advanced&#xD;
                  malignancies of the digestive system after failure of at least 1 line of standard&#xD;
                  therapy&#xD;
&#xD;
               -  Phase 1b Cohort C: cytologically or histologically confirmed advanced NSCLC&#xD;
                  without known epithelial growth factor receptor (EGFR) mutation and anaplastic&#xD;
                  lymphoma kinase (ALK) rearrangement after failure of 1st line standard therapy&#xD;
&#xD;
               -  Phase 1b Cohort D: treatment naive cytologically or histologically confirmed&#xD;
                  inoperable locally advanced (stage IIIB) or advanced (stage IV) nsNSCLC without&#xD;
                  known EGFR mutation and ALK rearrangement, participants with disease recurrence&#xD;
                  or progression within 6 months after completion of prior platinum doublet-based&#xD;
                  chemotherapy regimen as neoadjuvant or adjuvant therapy are not eligible&#xD;
&#xD;
               -  Phase 1b Cohort E: Cytologically or histologically confirmed, treatment naïve&#xD;
                  locally advanced, recurrent or metastatic squamous NSCLC without known EGFR&#xD;
                  mutation and ALK rearrangement. Participants with Stage IIIB NSCLC who progressed&#xD;
                  within 6 months after completion of platinum-based chemotherapy are not eligible.&#xD;
&#xD;
               -  Phase 1b Cohort F: Histologically confirmed locally advanced, recurrent or&#xD;
                  metastatic gastric or esophagogastric junction adenocarcinoma without known HER2&#xD;
                  amplification.&#xD;
&#xD;
               -  Phase 1b Cohort G: Cytologically or histologically confirmed, treatment naïve&#xD;
                  locally advanced, recurrent or metastatic high grade(G3) neuroendocrine tumor&#xD;
                  with Ki-67&gt;20%.&#xD;
&#xD;
               -  Phase 1b Cohort H: Cytologically or histologically confirmed advanced high&#xD;
                  grade(G3) neuroendocrine tumor with Ki-67&gt;20% after failure of first line&#xD;
                  standard therapy. Participants progressed within 6 months after completion of&#xD;
                  adjuvant or neoadjuvant chemotherapy are eligible.&#xD;
&#xD;
          -  At least 1 measurable site of disease per RECIST v1.1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment of any antibody of PD-1 or PD-L1&#xD;
&#xD;
          -  Prior treatment of ipilimumab, unless all the following requirements are met:&#xD;
&#xD;
               -  Full resolution of ipilimumab related adverse effects (including immune related&#xD;
                  adverse effects) and no treatment for these adverse events (AEs) for at least 4&#xD;
                  weeks prior to the time of enrollment&#xD;
&#xD;
               -  Minimum of 12 weeks from the first dose of ipilimumab and &gt;6 weeks from the last&#xD;
                  dose&#xD;
&#xD;
               -  No history of severe immune related adverse effects from ipilimumab (CTCAE Grade&#xD;
                  4; CTCAE Grade 3 requiring treatment &gt;4 weeks)&#xD;
&#xD;
               -  Unequivocal PD following a dose of ipilimumab&#xD;
&#xD;
          -  HIV infection&#xD;
&#xD;
          -  Active HBV or HCV infection&#xD;
&#xD;
          -  Uncontrolled complication including but not limited to :&#xD;
&#xD;
               -  Clinically significant cardiovascular disease such as uncontrolled or symptomatic&#xD;
                  arrhythmias or congestive heart failure&#xD;
&#xD;
               -  History of stroke, myocardial infarction or intracranial hemorrhage within 6&#xD;
                  months prior to the enrolment&#xD;
&#xD;
          -  History or risk of autoimmune disease&#xD;
&#xD;
          -  Known interstitial lung disease&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>The fifth medical center of the PLA general hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>https://doi.org/10.1016/j.jtho.2018.10.018</url>
    <description>Abstract for Cohort E on Jtho.2018</description>
  </link>
  <results_reference>
    <citation>Jiang H, Zheng Y, Qian J, Mao C, Xu X, Li N, Xiao C, Wang H, Teng L, Zhou H, Wang S, Zhu D, Peng B, Shen L, Xu N. Safety and efficacy of sintilimab combined with oxaliplatin/capecitabine as first-line treatment in patients with locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in a phase Ib clinical trial. BMC Cancer. 2020 Aug 14;20(1):760. doi: 10.1186/s12885-020-07251-z.</citation>
    <PMID>32795349</PMID>
  </results_reference>
  <results_reference>
    <citation>Jiang H, Zheng Y, Qian J, Mao C, Xu X, Li N, Xiao C, Wang H, Teng L, Zhou H, Wang S, Zhu D, Sun T, Yu Y, Guo W, Xu N. Efficacy and safety of sintilimab in combination with chemotherapy in previously untreated advanced or metastatic nonsquamous or squamous NSCLC: two cohorts of an open-label, phase 1b study. Cancer Immunol Immunother. 2021 Mar;70(3):857-868. doi: 10.1007/s00262-020-02738-x. Epub 2020 Oct 17.</citation>
    <PMID>33070260</PMID>
  </results_reference>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 8, 2016</study_first_submitted>
  <study_first_submitted_qc>October 15, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 18, 2016</study_first_posted>
  <results_first_submitted>October 21, 2020</results_first_submitted>
  <results_first_submitted_qc>February 18, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 21, 2021</results_first_posted>
  <last_update_submitted>February 18, 2021</last_update_submitted>
  <last_update_submitted_qc>February 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Pemetrexed</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>January 31, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/16/NCT02937116/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1)</title>
          <description>1mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="P2">
          <title>Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2)</title>
          <description>3mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="P3">
          <title>Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3)</title>
          <description>10mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="P4">
          <title>Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4)</title>
          <description>200mg intravenous Q3W, will be continued until disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="P5">
          <title>MEL: Sintilimab 200mg Q3W (Cohort A)</title>
          <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
        </group>
        <group group_id="P6">
          <title>Malignant Tumor of the Digestive System or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B)</title>
          <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
        </group>
        <group group_id="P7">
          <title>NSCLC: Sintilimab 200mg Q3W (Cohort C)</title>
          <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
        </group>
        <group group_id="P8">
          <title>nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D)</title>
          <description>Subjects received sintilimab 200mg in combination with cisplatin 75mg/m2 and pemetrexed 500mg/m2 intravenously every 3 weeks for upto 4 cycles, and those who haven't progressed will receive maintenance treatment of IBI308 200mg in combination with pemetrexed 500mg/m2 intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
        </group>
        <group group_id="P9">
          <title>scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E)</title>
          <description>Subjects received sintilimab 200mg and cisplatin 75mg/m2 intravenously every 3 weeks in combination with gemcitabine 1250mg/m2 intravenously day 1 and 8 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
        </group>
        <group group_id="P10">
          <title>Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F)</title>
          <description>Subjects received sintilimab 200mg and oxaliplatin 130mg/m2 intravenously every 3 weeks in combination with capecitabine 1000mg/m2 orally day 1 to 14 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
        </group>
        <group group_id="P11">
          <title>Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G)</title>
          <description>Subjects received sintilimab 200mg in combination with Cisplatin 75mg/m2 intravenously Day 1 and Etoposide 100mg/m2 intravenously Day 1-3 every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
        </group>
        <group group_id="P12">
          <title>Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H)</title>
          <description>Subjects received sintilimab 200mg intravenously Day 1 in combination with Irinotecan 125mg/m2 intravenously Day 1 and 8, and 5-FU 1000mg/m2 intravenously Day 1-3 every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="22"/>
                <participants group_id="P6" count="87"/>
                <participants group_id="P7" count="37"/>
                <participants group_id="P8" count="21"/>
                <participants group_id="P9" count="20"/>
                <participants group_id="P10" count="20"/>
                <participants group_id="P11" count="7"/>
                <participants group_id="P12" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="22"/>
                <participants group_id="P6" count="87"/>
                <participants group_id="P7" count="37"/>
                <participants group_id="P8" count="21"/>
                <participants group_id="P9" count="20"/>
                <participants group_id="P10" count="20"/>
                <participants group_id="P11" count="7"/>
                <participants group_id="P12" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1)</title>
          <description>1mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="B2">
          <title>Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2)</title>
          <description>3mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="B3">
          <title>Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3)</title>
          <description>10mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="B4">
          <title>Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4)</title>
          <description>200mg intravenous Q3W, will be continued until disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="B5">
          <title>MEL: Sintilimab 200mg Q3W (Cohort A)</title>
          <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
        </group>
        <group group_id="B6">
          <title>Malignant Tumor of the Digestive System or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B)</title>
          <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
        </group>
        <group group_id="B7">
          <title>NSCLC: Sintilimab 200mg Q3W (Cohort C)</title>
          <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
        </group>
        <group group_id="B8">
          <title>nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D)</title>
          <description>Subjects received sintilimab 200mg in combination with cisplatin 75mg/m2 and pemetrexed 500mg/m2 intravenously every 3 weeks for upto 4 cycles, and those who haven't progressed will receive maintenance treatment of IBI308 200mg in combination with pemetrexed 500mg/m2 intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
        </group>
        <group group_id="B9">
          <title>scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E)</title>
          <description>Subjects received sintilimab 200mg and cisplatin 75mg/m2 intravenously every 3 weeks in combination with gemcitabine 1250mg/m2 intravenously day 1 and 8 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
        </group>
        <group group_id="B10">
          <title>Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F)</title>
          <description>Subjects received sintilimab 200mg and oxaliplatin 130mg/m2 intravenously every 3 weeks in combination with capecitabine 1000mg/m2 orally day 1 to 14 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
        </group>
        <group group_id="B11">
          <title>Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G)</title>
          <description>Subjects received sintilimab 200mg in combination with Cisplatin 75mg/m2 intravenously Day 1 and Etoposide 100mg/m2 intravenously Day 1-3 every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
        </group>
        <group group_id="B12">
          <title>Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H)</title>
          <description>Subjects received sintilimab 200mg intravenously Day 1 in combination with Irinotecan 125mg/m2 intravenously Day 1 and 8, and 5-FU 1000mg/m2 intravenously Day 1-3 every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
        </group>
        <group group_id="B13">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="22"/>
            <count group_id="B6" value="87"/>
            <count group_id="B7" value="37"/>
            <count group_id="B8" value="21"/>
            <count group_id="B9" value="20"/>
            <count group_id="B10" value="20"/>
            <count group_id="B11" value="7"/>
            <count group_id="B12" value="7"/>
            <count group_id="B13" value="233"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44.33" spread="17.010"/>
                    <measurement group_id="B2" value="46" spread="15.524"/>
                    <measurement group_id="B3" value="48" spread="6.557"/>
                    <measurement group_id="B4" value="50" spread="16.093"/>
                    <measurement group_id="B5" value="49.13" spread="13.061"/>
                    <measurement group_id="B6" value="52.27" spread="11.280"/>
                    <measurement group_id="B7" value="55.35" spread="11.201"/>
                    <measurement group_id="B8" value="60.52" spread="6.539"/>
                    <measurement group_id="B9" value="62.30" spread="6.951"/>
                    <measurement group_id="B10" value="58.20" spread="8.600"/>
                    <measurement group_id="B11" value="62.86" spread="4.140"/>
                    <measurement group_id="B12" value="49.29" spread="11.912"/>
                    <measurement group_id="B13" value="54.54" spread="11.291"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="30"/>
                    <measurement group_id="B7" value="6"/>
                    <measurement group_id="B8" value="5"/>
                    <measurement group_id="B9" value="1"/>
                    <measurement group_id="B10" value="2"/>
                    <measurement group_id="B11" value="1"/>
                    <measurement group_id="B12" value="2"/>
                    <measurement group_id="B13" value="61"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="57"/>
                    <measurement group_id="B7" value="31"/>
                    <measurement group_id="B8" value="16"/>
                    <measurement group_id="B9" value="19"/>
                    <measurement group_id="B10" value="18"/>
                    <measurement group_id="B11" value="6"/>
                    <measurement group_id="B12" value="5"/>
                    <measurement group_id="B13" value="172"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B6" value="87"/>
                    <measurement group_id="B7" value="37"/>
                    <measurement group_id="B8" value="21"/>
                    <measurement group_id="B9" value="20"/>
                    <measurement group_id="B10" value="20"/>
                    <measurement group_id="B11" value="7"/>
                    <measurement group_id="B12" value="7"/>
                    <measurement group_id="B13" value="233"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B6" value="87"/>
                    <measurement group_id="B7" value="37"/>
                    <measurement group_id="B8" value="21"/>
                    <measurement group_id="B9" value="20"/>
                    <measurement group_id="B10" value="20"/>
                    <measurement group_id="B11" value="7"/>
                    <measurement group_id="B12" value="7"/>
                    <measurement group_id="B13" value="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Experiencing Dose-limiting Toxicities (DLTs)</title>
        <time_frame>Up to 28 days in Cycle 1</time_frame>
        <population>All participants in Parts A1 to A4 who received ≥1 dose of study treatment and either 1) had a DLT in Cycle 1 or 2) received ≥90% of the prescribed dose of Sintilimab in Cycle 1 and completed all safety evaluations ≥28 days after the first administration of Sintilimab without experiencing DLT. Per protocol, cohort A to H were not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1)</title>
            <description>1mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2)</title>
            <description>3mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3)</title>
            <description>10mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4)</title>
            <description>200mg intravenous Q3W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O5">
            <title>MEL: Sintilimab 200mg Q3W (Cohort A)</title>
            <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O6">
            <title>Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B)</title>
            <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O7">
            <title>NSCLC: Sintilimab 200mg Q3W (Cohort C)</title>
            <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O8">
            <title>nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D)</title>
            <description>Subjects received sintilimab 200mg in combination with cisplatin 75mg/m2 and pemetrexed 500mg/m2 intravenously every 3 weeks for upto 4 cycles, and those who haven't progressed will receive maintenance treatment of IBI308 200mg in combination with pemetrexed 500mg/m2 intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O9">
            <title>scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E)</title>
            <description>Subjects received sintilimab 200mg and cisplatin 75mg/m2 intravenously every 3 weeks in combination with gemcitabine 1250mg/m2 intravenously day 1 and 8 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O10">
            <title>Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F)</title>
            <description>Subjects received sintilimab 200mg and oxaliplatin 130mg/m2 intravenously every 3 weeks in combination with capecitabine 1000mg/m2 orally day 1 to 14 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O11">
            <title>Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G)</title>
            <description>Subjects received sintilimab 200mg in combination with Cisplatin 75mg/m2 intravenously Day 1 and Etoposide 100mg/m2 intravenously Day 1-3 every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O12">
            <title>Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H)</title>
            <description>Subjects received sintilimab 200mg intravenously Day 1 in combination with Irinotecan 125mg/m2 intravenously Day 1 and 8, and 5-FU 1000mg/m2 intravenously Day 1-3 every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Experiencing Dose-limiting Toxicities (DLTs)</title>
          <population>All participants in Parts A1 to A4 who received ≥1 dose of study treatment and either 1) had a DLT in Cycle 1 or 2) received ≥90% of the prescribed dose of Sintilimab in Cycle 1 and completed all safety evaluations ≥28 days after the first administration of Sintilimab without experiencing DLT. Per protocol, cohort A to H were not analyzed.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of All Study Participants Who Demonstrate a Tumor Response</title>
        <time_frame>Through out the study (up to 2 years)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1)</title>
            <description>1mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2)</title>
            <description>3mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3)</title>
            <description>10mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4)</title>
            <description>200mg intravenous Q3W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O5">
            <title>MEL: Sintilimab 200mg Q3W (Cohort A)</title>
            <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O6">
            <title>Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B)</title>
            <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O7">
            <title>NSCLC: Sintilimab 200mg Q3W (Cohort C)</title>
            <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O8">
            <title>nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D)</title>
            <description>Subjects received sintilimab 200mg in combination with cisplatin 75mg/m2 and pemetrexed 500mg/m2 intravenously every 3 weeks for upto 4 cycles, and those who haven't progressed will receive maintenance treatment of IBI308 200mg in combination with pemetrexed 500mg/m2 intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O9">
            <title>scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E)</title>
            <description>Subjects received sintilimab 200mg and cisplatin 75mg/m2 intravenously every 3 weeks in combination with gemcitabine 1250mg/m2 intravenously day 1 and 8 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O10">
            <title>Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F)</title>
            <description>Subjects received sintilimab 200mg and oxaliplatin 130mg/m2 intravenously every 3 weeks in combination with capecitabine 1000mg/m2 orally day 1 to 14 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O11">
            <title>Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G)</title>
            <description>Subjects received sintilimab 200mg in combination with Cisplatin 75mg/m2 intravenously Day 1 and Etoposide 100mg/m2 intravenously Day 1-3 every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O12">
            <title>Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H)</title>
            <description>Subjects received sintilimab 200mg intravenously Day 1 in combination with Irinotecan 125mg/m2 intravenously Day 1 and 8, and 5-FU 1000mg/m2 intravenously Day 1-3 every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of All Study Participants Who Demonstrate a Tumor Response</title>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="87"/>
                <count group_id="O7" value="37"/>
                <count group_id="O8" value="21"/>
                <count group_id="O9" value="20"/>
                <count group_id="O10" value="20"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="1"/>
                    <measurement group_id="O6" value="13"/>
                    <measurement group_id="O7" value="5"/>
                    <measurement group_id="O8" value="13"/>
                    <measurement group_id="O9" value="11"/>
                    <measurement group_id="O10" value="17"/>
                    <measurement group_id="O11" value="3"/>
                    <measurement group_id="O12" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Objective Response Rate (ORR) According to RECIST 1.1 as Assessed by Independent Review Committee by Investigator</title>
        <description>ORR was defined as the percentage of participants in the analysis population who had achieved BOR of CR or PR according to RECIST 1.1.</description>
        <time_frame>Through out the study (up to 2 years)</time_frame>
        <population>Participants from cohort A to H that received ≥1 dose of study treatment. Per protocol, Part A1 to A4 (dose-escalation) was not analyzed for efficacy.</population>
        <group_list>
          <group group_id="O1">
            <title>Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1)</title>
            <description>1mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2)</title>
            <description>3mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3)</title>
            <description>10mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4)</title>
            <description>200mg intravenous Q3W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O5">
            <title>MEL: Sintilimab 200mg Q3W (Cohort A)</title>
            <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O6">
            <title>Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B)</title>
            <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O7">
            <title>NSCLC: Sintilimab 200mg Q3W (Cohort C)</title>
            <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O8">
            <title>nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D)</title>
            <description>Subjects received sintilimab 200mg in combination with cisplatin 75mg/m2 and pemetrexed 500mg/m2 intravenously every 3 weeks for upto 4 cycles, and those who haven't progressed will receive maintenance treatment of IBI308 200mg in combination with pemetrexed 500mg/m2 intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O9">
            <title>scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E)</title>
            <description>Subjects received sintilimab 200mg and cisplatin 75mg/m2 intravenously every 3 weeks in combination with gemcitabine 1250mg/m2 intravenously day 1 and 8 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O10">
            <title>Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F)</title>
            <description>Subjects received sintilimab 200mg and oxaliplatin 130mg/m2 intravenously every 3 weeks in combination with capecitabine 1000mg/m2 orally day 1 to 14 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O11">
            <title>Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G)</title>
            <description>Subjects received sintilimab 200mg in combination with Cisplatin 75mg/m2 intravenously Day 1 and Etoposide 100mg/m2 intravenously Day 1-3 every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O12">
            <title>Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H)</title>
            <description>Subjects received sintilimab 200mg intravenously Day 1 in combination with Irinotecan 125mg/m2 intravenously Day 1 and 8, and 5-FU 1000mg/m2 intravenously Day 1-3 every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Objective Response Rate (ORR) According to RECIST 1.1 as Assessed by Independent Review Committee by Investigator</title>
          <description>ORR was defined as the percentage of participants in the analysis population who had achieved BOR of CR or PR according to RECIST 1.1.</description>
          <population>Participants from cohort A to H that received ≥1 dose of study treatment. Per protocol, Part A1 to A4 (dose-escalation) was not analyzed for efficacy.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="87"/>
                <count group_id="O7" value="37"/>
                <count group_id="O8" value="21"/>
                <count group_id="O9" value="20"/>
                <count group_id="O10" value="20"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="4.5" lower_limit="0.1" upper_limit="22.8"/>
                    <measurement group_id="O6" value="14.9" lower_limit="8.2" upper_limit="24.2"/>
                    <measurement group_id="O7" value="13.5" lower_limit="4.5" upper_limit="28.8"/>
                    <measurement group_id="O8" value="61.9" lower_limit="38.4" upper_limit="81.9"/>
                    <measurement group_id="O9" value="55.0" lower_limit="31.5" upper_limit="76.9"/>
                    <measurement group_id="O10" value="85.0" lower_limit="62.1" upper_limit="96.8"/>
                    <measurement group_id="O11" value="42.9" lower_limit="9.9" upper_limit="81.6"/>
                    <measurement group_id="O12" value="14.3" lower_limit="0.4" upper_limit="57.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PFS According to RECIST 1.1 as Assessed by Investigator</title>
        <time_frame>Through out the study (up to 2 years)</time_frame>
        <population>Participants from cohort A to H that received ≥1 dose of study treatment. Per protocol, Part A1 to A4 (dose-escalation) was not analyzed for efficacy.</population>
        <group_list>
          <group group_id="O1">
            <title>Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1)</title>
            <description>1mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2)</title>
            <description>3mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3)</title>
            <description>10mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4)</title>
            <description>200mg intravenous Q3W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O5">
            <title>MEL: Sintilimab 200mg Q3W (Cohort A)</title>
            <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O6">
            <title>Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B)</title>
            <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O7">
            <title>NSCLC: Sintilimab 200mg Q3W (Cohort C)</title>
            <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O8">
            <title>nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D)</title>
            <description>Subjects received sintilimab 200mg in combination with cisplatin 75mg/m2 and pemetrexed 500mg/m2 intravenously every 3 weeks for upto 4 cycles, and those who haven't progressed will receive maintenance treatment of IBI308 200mg in combination with pemetrexed 500mg/m2 intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O9">
            <title>scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E)</title>
            <description>Subjects received sintilimab 200mg and cisplatin 75mg/m2 intravenously every 3 weeks in combination with gemcitabine 1250mg/m2 intravenously day 1 and 8 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O10">
            <title>Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F)</title>
            <description>Subjects received sintilimab 200mg and oxaliplatin 130mg/m2 intravenously every 3 weeks in combination with capecitabine 1000mg/m2 orally day 1 to 14 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O11">
            <title>Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G)</title>
            <description>Subjects received sintilimab 200mg in combination with Cisplatin 75mg/m2 intravenously Day 1 and Etoposide 100mg/m2 intravenously Day 1-3 every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O12">
            <title>Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H)</title>
            <description>Subjects received sintilimab 200mg intravenously Day 1 in combination with Irinotecan 125mg/m2 intravenously Day 1 and 8, and 5-FU 1000mg/m2 intravenously Day 1-3 every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>PFS According to RECIST 1.1 as Assessed by Investigator</title>
          <population>Participants from cohort A to H that received ≥1 dose of study treatment. Per protocol, Part A1 to A4 (dose-escalation) was not analyzed for efficacy.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="87"/>
                <count group_id="O7" value="37"/>
                <count group_id="O8" value="21"/>
                <count group_id="O9" value="20"/>
                <count group_id="O10" value="20"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="62.0" lower_limit="59.0" upper_limit="125.0"/>
                    <measurement group_id="O6" value="66.0" lower_limit="64.0" upper_limit="95.0"/>
                    <measurement group_id="O7" value="84.0" lower_limit="60.0" upper_limit="187.0"/>
                    <measurement group_id="O8" value="377.0" lower_limit="92.0" upper_limit="NA">PFS range upper limit of 95% CI not reached</measurement>
                    <measurement group_id="O9" value="194.0" lower_limit="160.0" upper_limit="239.0"/>
                    <measurement group_id="O10" value="230.0" lower_limit="189.0" upper_limit="287.0"/>
                    <measurement group_id="O11" value="NA" lower_limit="NA" upper_limit="NA">Median PFS and PFS range lower and upper limit of 95% CI not reached (no disease progression by last progression assessment)</measurement>
                    <measurement group_id="O12" value="NA" lower_limit="68.0" upper_limit="NA">Median PFS and PFS range upper limit of 95% CI not reached</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>DOR According to RECIST 1.1 as Assessed by Investigator</title>
        <time_frame>Through out the study (up to 2 years)</time_frame>
        <population>Participants from cohort A to H that received ≥1 dose of study treatment. Per protocol, Part A1 to A4 (dose-escalation) was not analyzed for efficacy.</population>
        <group_list>
          <group group_id="O1">
            <title>Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1)</title>
            <description>1mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2)</title>
            <description>3mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3)</title>
            <description>10mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4)</title>
            <description>200mg intravenous Q3W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O5">
            <title>MEL: Sintilimab 200mg Q3W (Cohort A)</title>
            <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O6">
            <title>Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B)</title>
            <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O7">
            <title>NSCLC: Sintilimab 200mg Q3W (Cohort C)</title>
            <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O8">
            <title>nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D)</title>
            <description>Subjects received sintilimab 200mg in combination with cisplatin 75mg/m2 and pemetrexed 500mg/m2 intravenously every 3 weeks for upto 4 cycles, and those who haven't progressed will receive maintenance treatment of IBI308 200mg in combination with pemetrexed 500mg/m2 intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O9">
            <title>scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E)</title>
            <description>Subjects received sintilimab 200mg and cisplatin 75mg/m2 intravenously every 3 weeks in combination with gemcitabine 1250mg/m2 intravenously day 1 and 8 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O10">
            <title>Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F)</title>
            <description>Subjects received sintilimab 200mg and oxaliplatin 130mg/m2 intravenously every 3 weeks in combination with capecitabine 1000mg/m2 orally day 1 to 14 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O11">
            <title>Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G)</title>
            <description>Subjects received sintilimab 200mg in combination with Cisplatin 75mg/m2 intravenously Day 1 and Etoposide 100mg/m2 intravenously Day 1-3 every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O12">
            <title>Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H)</title>
            <description>Subjects received sintilimab 200mg intravenously Day 1 in combination with Irinotecan 125mg/m2 intravenously Day 1 and 8, and 5-FU 1000mg/m2 intravenously Day 1-3 every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>DOR According to RECIST 1.1 as Assessed by Investigator</title>
          <population>Participants from cohort A to H that received ≥1 dose of study treatment. Per protocol, Part A1 to A4 (dose-escalation) was not analyzed for efficacy.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="87"/>
                <count group_id="O7" value="37"/>
                <count group_id="O8" value="21"/>
                <count group_id="O9" value="20"/>
                <count group_id="O10" value="20"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="NA" lower_limit="NA" upper_limit="NA">Median DOR and DOR lower and upper limit not reached</measurement>
                    <measurement group_id="O6" value="NA" lower_limit="86.0" upper_limit="NA">Median DOR and DOR upper limit not reached (no progressive disease by time of last disease assessment)</measurement>
                    <measurement group_id="O7" value="368.0" lower_limit="190.0" upper_limit="NA">DOR upper limit not reached</measurement>
                    <measurement group_id="O8" value="NA" lower_limit="NA" upper_limit="NA">Median DOR and DOR lower and upper limit not reached</measurement>
                    <measurement group_id="O9" value="170.5" lower_limit="58.0" upper_limit="NA">DORupper limit not reached</measurement>
                    <measurement group_id="O10" value="181.0" lower_limit="146.0" upper_limit="221.0"/>
                    <measurement group_id="O11" value="NA" lower_limit="NA" upper_limit="NA">Median DOR and DOR lower and upper limit of 95% CI not reached</measurement>
                    <measurement group_id="O12" value="NA" lower_limit="NA" upper_limit="NA">Median DOR and DOR lower and upper limit of 95% CI not reached</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>TTR According to RECIST 1.1 as Assessed by Investigator</title>
        <time_frame>Through out the study (up to 2 years)</time_frame>
        <population>Participants from cohort A to H that received ≥1 dose of study treatment. Per protocol, Part A1 to A4 (dose-escalation) was not analyzed for efficacy.</population>
        <group_list>
          <group group_id="O1">
            <title>Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1)</title>
            <description>1mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2)</title>
            <description>3mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3)</title>
            <description>10mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4)</title>
            <description>200mg intravenous Q3W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O5">
            <title>MEL: Sintilimab 200mg Q3W (Cohort A)</title>
            <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O6">
            <title>Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B)</title>
            <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O7">
            <title>NSCLC: Sintilimab 200mg Q3W (Cohort C)</title>
            <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O8">
            <title>nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D)</title>
            <description>Subjects received sintilimab 200mg in combination with cisplatin 75mg/m2 and pemetrexed 500mg/m2 intravenously every 3 weeks for upto 4 cycles, and those who haven't progressed will receive maintenance treatment of IBI308 200mg in combination with pemetrexed 500mg/m2 intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O9">
            <title>scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E)</title>
            <description>Subjects received sintilimab 200mg and cisplatin 75mg/m2 intravenously every 3 weeks in combination with gemcitabine 1250mg/m2 intravenously day 1 and 8 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O10">
            <title>Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F)</title>
            <description>Subjects received sintilimab 200mg and oxaliplatin 130mg/m2 intravenously every 3 weeks in combination with capecitabine 1000mg/m2 orally day 1 to 14 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O11">
            <title>Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G)</title>
            <description>Subjects received sintilimab 200mg in combination with Cisplatin 75mg/m2 intravenously Day 1 and Etoposide 100mg/m2 intravenously Day 1-3 every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O12">
            <title>Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H)</title>
            <description>Subjects received sintilimab 200mg intravenously Day 1 in combination with Irinotecan 125mg/m2 intravenously Day 1 and 8, and 5-FU 1000mg/m2 intravenously Day 1-3 every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>TTR According to RECIST 1.1 as Assessed by Investigator</title>
          <population>Participants from cohort A to H that received ≥1 dose of study treatment. Per protocol, Part A1 to A4 (dose-escalation) was not analyzed for efficacy.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="87"/>
                <count group_id="O7" value="37"/>
                <count group_id="O8" value="21"/>
                <count group_id="O9" value="20"/>
                <count group_id="O10" value="20"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="63.0" lower_limit="NA" upper_limit="NA">TTR louwer and upper limit not reached</measurement>
                    <measurement group_id="O6" value="64.0" lower_limit="61.0" upper_limit="70.0"/>
                    <measurement group_id="O7" value="63.0" lower_limit="60.0" upper_limit="189.0"/>
                    <measurement group_id="O8" value="63.0" lower_limit="62.0" upper_limit="120.0"/>
                    <measurement group_id="O9" value="62.0" lower_limit="58.0" upper_limit="68.0"/>
                    <measurement group_id="O10" value="63.0" lower_limit="62.0" upper_limit="65.0"/>
                    <measurement group_id="O11" value="62.0" lower_limit="62.0" upper_limit="63.0"/>
                    <measurement group_id="O12" value="62.0" lower_limit="62.0" upper_limit="62.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OS for Participants</title>
        <time_frame>Through out the study</time_frame>
        <population>Participants from cohort A to H that received ≥1 dose of study treatment. Per protocol, Part A1 to A4 (dose-escalation) was not analyzed for efficacy.</population>
        <group_list>
          <group group_id="O1">
            <title>Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1)</title>
            <description>1mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2)</title>
            <description>3mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3)</title>
            <description>10mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4)</title>
            <description>200mg intravenous Q3W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O5">
            <title>MEL: Sintilimab 200mg Q3W (Cohort A)</title>
            <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O6">
            <title>Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B)</title>
            <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O7">
            <title>NSCLC: Sintilimab 200mg Q3W (Cohort C)</title>
            <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O8">
            <title>nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D)</title>
            <description>Subjects received sintilimab 200mg in combination with cisplatin 75mg/m2 and pemetrexed 500mg/m2 intravenously every 3 weeks for upto 4 cycles, and those who haven't progressed will receive maintenance treatment of IBI308 200mg in combination with pemetrexed 500mg/m2 intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O9">
            <title>scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E)</title>
            <description>Subjects received sintilimab 200mg and cisplatin 75mg/m2 intravenously every 3 weeks in combination with gemcitabine 1250mg/m2 intravenously day 1 and 8 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O10">
            <title>Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F)</title>
            <description>Subjects received sintilimab 200mg and oxaliplatin 130mg/m2 intravenously every 3 weeks in combination with capecitabine 1000mg/m2 orally day 1 to 14 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O11">
            <title>Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G)</title>
            <description>Subjects received sintilimab 200mg in combination with Cisplatin 75mg/m2 intravenously Day 1 and Etoposide 100mg/m2 intravenously Day 1-3 every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O12">
            <title>Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H)</title>
            <description>Subjects received sintilimab 200mg intravenously Day 1 in combination with Irinotecan 125mg/m2 intravenously Day 1 and 8, and 5-FU 1000mg/m2 intravenously Day 1-3 every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>OS for Participants</title>
          <population>Participants from cohort A to H that received ≥1 dose of study treatment. Per protocol, Part A1 to A4 (dose-escalation) was not analyzed for efficacy.</population>
          <units>Days</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
                <count group_id="O5" value="22"/>
                <count group_id="O6" value="87"/>
                <count group_id="O7" value="37"/>
                <count group_id="O8" value="21"/>
                <count group_id="O9" value="20"/>
                <count group_id="O10" value="20"/>
                <count group_id="O11" value="7"/>
                <count group_id="O12" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O5" value="518.0" lower_limit="349.0" upper_limit="NA">OS range upper limit not reached</measurement>
                    <measurement group_id="O6" value="342.0" lower_limit="218.0" upper_limit="441.0"/>
                    <measurement group_id="O7" value="431.0" lower_limit="196.0" upper_limit="562.0"/>
                    <measurement group_id="O8" value="566.0" lower_limit="158.0" upper_limit="NA">OS range upper limit not reached</measurement>
                    <measurement group_id="O9" value="461.0" lower_limit="308.0" upper_limit="NA">OS range upper limit not reached</measurement>
                    <measurement group_id="O10" value="NA" lower_limit="287.0" upper_limit="NA">Median OS and OS range upper limit not reached</measurement>
                    <measurement group_id="O11" value="NA" lower_limit="NA" upper_limit="NA">Median OS and OS range lower and upper limit of 95% CI not reached (no death by last assessment)</measurement>
                    <measurement group_id="O12" value="NA" lower_limit="NA" upper_limit="NA">Median OS and OS range lower and upper limit of 95% CI not reached (no death by last assessment)</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Concentration-time Curve From Zero Time (Predose) to the Time of the Last Measurable Concentration (AUC0-t)</title>
        <time_frame>Cycle 1: pre-dose, post-dose at 0, 1, and 6 hours, and Days 2, 3, 8, 15, and 22, and 29</time_frame>
        <population>All participants in Parts A1 to A4 receiving a single dose of drug during Cycle 1 (28 days) and having available AUC 0-t data. Per protocol, participants in cohort A to H were not included in the escalating dose PK analysis..</population>
        <group_list>
          <group group_id="O1">
            <title>Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1)</title>
            <description>1mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2)</title>
            <description>3mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3)</title>
            <description>10mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4)</title>
            <description>200mg intravenous Q3W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O5">
            <title>MEL: Sintilimab 200mg Q3W (Cohort A)</title>
            <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O6">
            <title>Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B)</title>
            <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O7">
            <title>NSCLC: Sintilimab 200mg Q3W (Cohort C)</title>
            <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O8">
            <title>nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D)</title>
            <description>Subjects received sintilimab 200mg in combination with cisplatin 75mg/m2 and pemetrexed 500mg/m2 intravenously every 3 weeks for upto 4 cycles, and those who haven't progressed will receive maintenance treatment of IBI308 200mg in combination with pemetrexed 500mg/m2 intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O9">
            <title>scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E)</title>
            <description>Subjects received sintilimab 200mg and cisplatin 75mg/m2 intravenously every 3 weeks in combination with gemcitabine 1250mg/m2 intravenously day 1 and 8 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O10">
            <title>Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F)</title>
            <description>Subjects received sintilimab 200mg and oxaliplatin 130mg/m2 intravenously every 3 weeks in combination with capecitabine 1000mg/m2 orally day 1 to 14 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O11">
            <title>Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G)</title>
            <description>Subjects received sintilimab 200mg in combination with Cisplatin 75mg/m2 intravenously Day 1 and Etoposide 100mg/m2 intravenously Day 1-3 every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O12">
            <title>Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H)</title>
            <description>Subjects received sintilimab 200mg intravenously Day 1 in combination with Irinotecan 125mg/m2 intravenously Day 1 and 8, and 5-FU 1000mg/m2 intravenously Day 1-3 every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Concentration-time Curve From Zero Time (Predose) to the Time of the Last Measurable Concentration (AUC0-t)</title>
          <population>All participants in Parts A1 to A4 receiving a single dose of drug during Cycle 1 (28 days) and having available AUC 0-t data. Per protocol, participants in cohort A to H were not included in the escalating dose PK analysis..</population>
          <units>h*ug/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4800" spread="8.2"/>
                    <measurement group_id="O2" value="12300" spread="35.2"/>
                    <measurement group_id="O3" value="39800" spread="14.5"/>
                    <measurement group_id="O4" value="10800" spread="49.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Concentration (Cmax) of Sintilimab in Solid Tumor Participants</title>
        <time_frame>Cycle 1: pre-dose, post-dose at 0, 1, 6 hours, and Days 2, 3, 8, 15, and 22, and 29</time_frame>
        <population>All participants in Parts A1 to A4 receiving a single dose of drug during Cycle 1 (28 days) and having available Cmax data. Per protocol, participants in cohort A to H were not included in the escalating dose PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1)</title>
            <description>1mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2)</title>
            <description>3mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3)</title>
            <description>10mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4)</title>
            <description>200mg intravenous Q3W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O5">
            <title>MEL: Sintilimab 200mg Q3W (Cohort A)</title>
            <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O6">
            <title>Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B)</title>
            <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O7">
            <title>NSCLC: Sintilimab 200mg Q3W (Cohort C)</title>
            <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O8">
            <title>nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D)</title>
            <description>Subjects received sintilimab 200mg in combination with cisplatin 75mg/m2 and pemetrexed 500mg/m2 intravenously every 3 weeks for upto 4 cycles, and those who haven't progressed will receive maintenance treatment of IBI308 200mg in combination with pemetrexed 500mg/m2 intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O9">
            <title>scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E)</title>
            <description>Subjects received sintilimab 200mg and cisplatin 75mg/m2 intravenously every 3 weeks in combination with gemcitabine 1250mg/m2 intravenously day 1 and 8 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O10">
            <title>Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F)</title>
            <description>Subjects received sintilimab 200mg and oxaliplatin 130mg/m2 intravenously every 3 weeks in combination with capecitabine 1000mg/m2 orally day 1 to 14 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O11">
            <title>Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G)</title>
            <description>Subjects received sintilimab 200mg in combination with Cisplatin 75mg/m2 intravenously Day 1 and Etoposide 100mg/m2 intravenously Day 1-3 every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O12">
            <title>Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H)</title>
            <description>Subjects received sintilimab 200mg intravenously Day 1 in combination with Irinotecan 125mg/m2 intravenously Day 1 and 8, and 5-FU 1000mg/m2 intravenously Day 1-3 every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Concentration (Cmax) of Sintilimab in Solid Tumor Participants</title>
          <population>All participants in Parts A1 to A4 receiving a single dose of drug during Cycle 1 (28 days) and having available Cmax data. Per protocol, participants in cohort A to H were not included in the escalating dose PK analysis.</population>
          <units>ug/ml</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.9" spread="11.3"/>
                    <measurement group_id="O2" value="69.7" spread="12.2"/>
                    <measurement group_id="O3" value="220" spread="13.4"/>
                    <measurement group_id="O4" value="54.6" spread="50.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Maximum Concentration (Tmax) of Sintilimab in Solid Tumor Participants</title>
        <time_frame>Cycle 1: pre-dose, post-dose at 0, 1, 6 hours, and Days 2, 3, 8, 15, and 22, and 29</time_frame>
        <population>All participants in Parts A1 to A4 receiving a single dose of drug during Cycle 1 (28 days) and having available Tmax data. Per protocol, participants in cohort A to H were not included in the escalating dose PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1)</title>
            <description>1mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2)</title>
            <description>3mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3)</title>
            <description>10mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4)</title>
            <description>200mg intravenous Q3W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O5">
            <title>MEL: Sintilimab 200mg Q3W (Cohort A)</title>
            <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O6">
            <title>Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B)</title>
            <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O7">
            <title>NSCLC: Sintilimab 200mg Q3W (Cohort C)</title>
            <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O8">
            <title>nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D)</title>
            <description>Subjects received sintilimab 200mg in combination with cisplatin 75mg/m2 and pemetrexed 500mg/m2 intravenously every 3 weeks for upto 4 cycles, and those who haven't progressed will receive maintenance treatment of IBI308 200mg in combination with pemetrexed 500mg/m2 intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O9">
            <title>scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E)</title>
            <description>Subjects received sintilimab 200mg and cisplatin 75mg/m2 intravenously every 3 weeks in combination with gemcitabine 1250mg/m2 intravenously day 1 and 8 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O10">
            <title>Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F)</title>
            <description>Subjects received sintilimab 200mg and oxaliplatin 130mg/m2 intravenously every 3 weeks in combination with capecitabine 1000mg/m2 orally day 1 to 14 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O11">
            <title>Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G)</title>
            <description>Subjects received sintilimab 200mg in combination with Cisplatin 75mg/m2 intravenously Day 1 and Etoposide 100mg/m2 intravenously Day 1-3 every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O12">
            <title>Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H)</title>
            <description>Subjects received sintilimab 200mg intravenously Day 1 in combination with Irinotecan 125mg/m2 intravenously Day 1 and 8, and 5-FU 1000mg/m2 intravenously Day 1-3 every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Maximum Concentration (Tmax) of Sintilimab in Solid Tumor Participants</title>
          <population>All participants in Parts A1 to A4 receiving a single dose of drug during Cycle 1 (28 days) and having available Tmax data. Per protocol, participants in cohort A to H were not included in the escalating dose PK analysis.</population>
          <units>hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.05" lower_limit="1.05" upper_limit="1.08"/>
                    <measurement group_id="O2" value="2.07" lower_limit="2.07" upper_limit="2.08"/>
                    <measurement group_id="O3" value="2.27" lower_limit="1.10" upper_limit="2.33"/>
                    <measurement group_id="O4" value="1.93" lower_limit="1.08" upper_limit="2.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Half-life (t1/2) of IBI308 in Plasma After Single Dose Administration</title>
        <time_frame>Cycle 1: pre-dose, post-dose at 0, 1, 6 hours, and Days 2, 3, 8, 15, and 22, and 29</time_frame>
        <population>All participants in Parts A1 to A4 receiving a single dose of drug during Cycle 1 (28 days) and having available T1/2 data. Per protocol, participants in cohort A to H were not included in the escalating dose PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1)</title>
            <description>1mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2)</title>
            <description>3mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3)</title>
            <description>10mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4)</title>
            <description>200mg intravenous Q3W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O5">
            <title>MEL: Sintilimab 200mg Q3W (Cohort A)</title>
            <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O6">
            <title>Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B)</title>
            <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O7">
            <title>NSCLC: Sintilimab 200mg Q3W (Cohort C)</title>
            <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O8">
            <title>nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D)</title>
            <description>Subjects received sintilimab 200mg in combination with cisplatin 75mg/m2 and pemetrexed 500mg/m2 intravenously every 3 weeks for upto 4 cycles, and those who haven't progressed will receive maintenance treatment of IBI308 200mg in combination with pemetrexed 500mg/m2 intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O9">
            <title>scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E)</title>
            <description>Subjects received sintilimab 200mg and cisplatin 75mg/m2 intravenously every 3 weeks in combination with gemcitabine 1250mg/m2 intravenously day 1 and 8 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O10">
            <title>Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F)</title>
            <description>Subjects received sintilimab 200mg and oxaliplatin 130mg/m2 intravenously every 3 weeks in combination with capecitabine 1000mg/m2 orally day 1 to 14 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O11">
            <title>Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G)</title>
            <description>Subjects received sintilimab 200mg in combination with Cisplatin 75mg/m2 intravenously Day 1 and Etoposide 100mg/m2 intravenously Day 1-3 every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O12">
            <title>Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H)</title>
            <description>Subjects received sintilimab 200mg intravenously Day 1 in combination with Irinotecan 125mg/m2 intravenously Day 1 and 8, and 5-FU 1000mg/m2 intravenously Day 1-3 every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>The Half-life (t1/2) of IBI308 in Plasma After Single Dose Administration</title>
          <population>All participants in Parts A1 to A4 receiving a single dose of drug during Cycle 1 (28 days) and having available T1/2 data. Per protocol, participants in cohort A to H were not included in the escalating dose PK analysis.</population>
          <units>Days</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17" spread="7.3"/>
                    <measurement group_id="O2" value="12.7" spread="44.6"/>
                    <measurement group_id="O3" value="12.5" spread="26.4"/>
                    <measurement group_id="O4" value="16.1" spread="32.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Volume of Distribution of IBI308 in Plasma After Single Dose Administration</title>
        <time_frame>Cycle 1: pre-dose, post-dose at 0, 1, 6 hours, and Days 2, 3, 8, 15, and 22, and 29</time_frame>
        <population>All participants in Parts A1 to A4 receiving a single dose of drug during Cycle 1 (28 days) and having available volume of distribution data. Per protocol, participants in cohort A to H were not included in the escalating dose PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1)</title>
            <description>1mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2)</title>
            <description>3mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3)</title>
            <description>10mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4)</title>
            <description>200mg intravenous Q3W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O5">
            <title>MEL: Sintilimab 200mg Q3W (Cohort A)</title>
            <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O6">
            <title>Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B)</title>
            <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O7">
            <title>NSCLC: Sintilimab 200mg Q3W (Cohort C)</title>
            <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O8">
            <title>nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D)</title>
            <description>Subjects received sintilimab 200mg in combination with cisplatin 75mg/m2 and pemetrexed 500mg/m2 intravenously every 3 weeks for upto 4 cycles, and those who haven't progressed will receive maintenance treatment of IBI308 200mg in combination with pemetrexed 500mg/m2 intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O9">
            <title>scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E)</title>
            <description>Subjects received sintilimab 200mg and cisplatin 75mg/m2 intravenously every 3 weeks in combination with gemcitabine 1250mg/m2 intravenously day 1 and 8 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O10">
            <title>Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F)</title>
            <description>Subjects received sintilimab 200mg and oxaliplatin 130mg/m2 intravenously every 3 weeks in combination with capecitabine 1000mg/m2 orally day 1 to 14 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O11">
            <title>Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G)</title>
            <description>Subjects received sintilimab 200mg in combination with Cisplatin 75mg/m2 intravenously Day 1 and Etoposide 100mg/m2 intravenously Day 1-3 every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O12">
            <title>Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H)</title>
            <description>Subjects received sintilimab 200mg intravenously Day 1 in combination with Irinotecan 125mg/m2 intravenously Day 1 and 8, and 5-FU 1000mg/m2 intravenously Day 1-3 every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Volume of Distribution of IBI308 in Plasma After Single Dose Administration</title>
          <population>All participants in Parts A1 to A4 receiving a single dose of drug during Cycle 1 (28 days) and having available volume of distribution data. Per protocol, participants in cohort A to H were not included in the escalating dose PK analysis.</population>
          <units>L</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.02" spread="24.0"/>
                    <measurement group_id="O2" value="5.14" spread="18.7"/>
                    <measurement group_id="O3" value="5.95" spread="10.5"/>
                    <measurement group_id="O4" value="7.2" spread="45.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clearance of IBI308 in Plasma After Single Dose Administration</title>
        <time_frame>Cycle 1: pre-dose, post-dose at 0, 1, 6 hours, and Days 2, 3, 8, 15, and 22, and 29</time_frame>
        <population>All participants in Parts A1 to A4 receiving a single dose of drug during Cycle 1 (28 days) and having available clearance data. Per protocol, participants in cohort A to H were not included in the escalating dose PK analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1)</title>
            <description>1mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O2">
            <title>Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2)</title>
            <description>3mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O3">
            <title>Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3)</title>
            <description>10mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O4">
            <title>Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4)</title>
            <description>200mg intravenous Q3W, will be continued until disease progression or unacceptable toxicity.</description>
          </group>
          <group group_id="O5">
            <title>MEL: Sintilimab 200mg Q3W (Cohort A)</title>
            <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O6">
            <title>Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B)</title>
            <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O7">
            <title>NSCLC: Sintilimab 200mg Q3W (Cohort C)</title>
            <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O8">
            <title>nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D)</title>
            <description>Subjects received sintilimab 200mg in combination with cisplatin 75mg/m2 and pemetrexed 500mg/m2 intravenously every 3 weeks for upto 4 cycles, and those who haven't progressed will receive maintenance treatment of IBI308 200mg in combination with pemetrexed 500mg/m2 intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O9">
            <title>scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E)</title>
            <description>Subjects received sintilimab 200mg and cisplatin 75mg/m2 intravenously every 3 weeks in combination with gemcitabine 1250mg/m2 intravenously day 1 and 8 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O10">
            <title>Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F)</title>
            <description>Subjects received sintilimab 200mg and oxaliplatin 130mg/m2 intravenously every 3 weeks in combination with capecitabine 1000mg/m2 orally day 1 to 14 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O11">
            <title>Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G)</title>
            <description>Subjects received sintilimab 200mg in combination with Cisplatin 75mg/m2 intravenously Day 1 and Etoposide 100mg/m2 intravenously Day 1-3 every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
          <group group_id="O12">
            <title>Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H)</title>
            <description>Subjects received sintilimab 200mg intravenously Day 1 in combination with Irinotecan 125mg/m2 intravenously Day 1 and 8, and 5-FU 1000mg/m2 intravenously Day 1-3 every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Clearance of IBI308 in Plasma After Single Dose Administration</title>
          <population>All participants in Parts A1 to A4 receiving a single dose of drug during Cycle 1 (28 days) and having available clearance data. Per protocol, participants in cohort A to H were not included in the escalating dose PK analysis.</population>
          <units>ml/h</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="0"/>
                <count group_id="O6" value="0"/>
                <count group_id="O7" value="0"/>
                <count group_id="O8" value="0"/>
                <count group_id="O9" value="0"/>
                <count group_id="O10" value="0"/>
                <count group_id="O11" value="0"/>
                <count group_id="O12" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.53" spread="20.7"/>
                    <measurement group_id="O2" value="11.7" spread="33.3"/>
                    <measurement group_id="O3" value="13.7" spread="15.9"/>
                    <measurement group_id="O4" value="12.9" spread="61.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to approximately 90 days (through Final Database cut-off date of 30-Oct-2017) for Phase Ia (Part A1 to A4); Up to approximately 90 days (through Final Database cut-off date of 17-Apr-2019) for Phase Ib (Cohort A to F); Up to approximately 90 days (through Final Database cut-off date of 30-Sep-2019) for Phase Ib (Cohort G to H);</time_frame>
      <desc>All adverse events, including serious adverse events, will be collected since the consent form is signed until 90th day after last administration of investigation products, either observed by investigator or by the spontaneous reported by subjects.</desc>
      <group_list>
        <group group_id="E1">
          <title>Solid Tumors: Sintilimab 1mg/kg Q2W (Part A1)</title>
          <description>1mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="E2">
          <title>Solid Tumors: Sintilimab 3mg/kg Q2W (Part A2)</title>
          <description>3mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="E3">
          <title>Solid Tumors: Sintilimab 10mg/kg Q2W (Part A3)</title>
          <description>10mg/kg intravenous Q2W, will be continued until disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="E4">
          <title>Solid Tumors: Sintilimab 200mg/kg Q3W (Part A4)</title>
          <description>200mg intravenous Q3W, will be continued until disease progression or unacceptable toxicity.</description>
        </group>
        <group group_id="E5">
          <title>MEL: Sintilimab 200mg Q3W (Cohort A)</title>
          <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
        </group>
        <group group_id="E6">
          <title>Malignant Tumor or Neuroendocrine Tumor: Sintilimab 200mg Q3W (Cohort B)</title>
          <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
        </group>
        <group group_id="E7">
          <title>NSCLC: Sintilimab 200mg Q3W (Cohort C)</title>
          <description>Subjects received sintilimab 200mg intravenous every 3 weeks and will be continued until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
        </group>
        <group group_id="E8">
          <title>nsNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort D)</title>
          <description>Subjects received sintilimab 200mg in combination with cisplatin 75mg/m2 and pemetrexed 500mg/m2 intravenously every 3 weeks for upto 4 cycles, and those who haven't progressed will receive maintenance treatment of IBI308 200mg in combination with pemetrexed 500mg/m2 intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
        </group>
        <group group_id="E9">
          <title>scNSCLC: Sintilimab 200mg Q3W + Chemotherapy (Cohort E)</title>
          <description>Subjects received sintilimab 200mg and cisplatin 75mg/m2 intravenously every 3 weeks in combination with gemcitabine 1250mg/m2 intravenously day 1 and 8 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
        </group>
        <group group_id="E10">
          <title>Gastric or Gastroesophageal Junction Adenocarcinoma: Sintilimab 200mg Q3W + Chemotherapy (Cohort F)</title>
          <description>Subjects received sintilimab 200mg and oxaliplatin 130mg/m2 intravenously every 3 weeks in combination with capecitabine 1000mg/m2 orally day 1 to 14 of every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
        </group>
        <group group_id="E11">
          <title>Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort G)</title>
          <description>Subjects received sintilimab 200mg in combination with Cisplatin 75mg/m2 intravenously Day 1 and Etoposide 100mg/m2 intravenously Day 1-3 every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
        </group>
        <group group_id="E12">
          <title>Neuroendocrine Tumors: Sintilimab 200mg Q3W + Chemotherapy (Cohort H)</title>
          <description>Subjects received sintilimab 200mg intravenously Day 1 in combination with Irinotecan 125mg/m2 intravenously Day 1 and 8, and 5-FU 1000mg/m2 intravenously Day 1-3 every 3 weeks for upto 6 cycles, and those those who haven't progressed will receive maintenance treatment of IBI308 200mg intravenously every 3 weeks until disease progression or unacceptable toxicity or withdrawal of informed consent or up to 24 months of treatment.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="57" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="25" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Bone marrow failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Oesophageal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Functional gastrointestinal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Autoimmune colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Gallbladder pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Biliary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pyopneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Tracheal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="82" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="35" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="19" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="20" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="20" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="37" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="17" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="12" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Coagulopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Neutrophilia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Atrioventricular block first degree</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Bundle branch block right</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Supraventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Thyroid mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Thyroiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Conjunctival hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Eyelid oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Xerophthalmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Gastric dilatation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hyperchlorhydria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Loose tooth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="23" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic function abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="7" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Sebaceous gland infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="22" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Amylase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="28" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Bilirubin conjugated increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood albumin decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood bilirubin unconjugated increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood lactate dehydrogenase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood potassium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood thyroid stimulating hormone decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood thyroid stimulating hormone increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood urea increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Blood uric acid increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Creatinine renal clearance increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Electrocardiogram QT prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T wave abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Electrocardiogram abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Electrocardiogram low voltage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Glucose urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Granulocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Mean cell haemoglobin concentration decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="16" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="10" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Neutrophil count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Occult blood positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="14" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="16" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Platelet count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Procalcitonin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Red blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Red blood cells urine positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Thyroid function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Thyroxine decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Thyroxine free decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Thyroxine free increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Thyroxine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Tri-iodothyronine decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Tri-iodothyronine free decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Tri-iodothyronine free increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Urine ketone body present</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="18" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="10" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>White blood cells urine positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Abnormal loss of weight</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Glucose tolerance impaired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypernatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="14" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypochloraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypoproteinaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Metabolic alkalosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Haemangioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cholinergic syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Breath holding</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Oliguria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="22" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Urethral pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pneumonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Tachypnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Urticaria papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Vitiligo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="22"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="87"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="37"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="20"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="20"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="7"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Yi Bo</name_or_title>
      <organization>Innovent Biologics (Suzhou) Co., Ltd. (seal)</organization>
      <phone>+8613382419112</phone>
      <email>jessica.yi@innoventbio.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

